At Progressive Oncology, one of the many treatment options is low-dose fractionated chemotherapy using insulin as a biologic response modifier.
For this therapy, chemotherapy drugs are selected according to conventional guidelines in concert with chemosensitivity studies and then administered IV at much lower than standard and in fractionated (divided into fractions) doses. The utilization of lower and fractionated doses of chemotherapy is based on physiologic and clinical experience which is augmented by using insulin which transports chemotherapy drugs across cancer cell membranes. Insulin attaches to insulin receptors on all cells, but cancer cells have significantly more insulin receptors and therefore chemo drugs are transported into cancer cells at a higher rate than into normal cells. In other words, insulin acts to target the chemotherapy drugs preferentially to cancer cells.
Based on clinical experience this kind of therapy can also minimize side effects of chemotherapy and improve quality of life as compared to receiving conventional-dose chemotherapy.